Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03817645
Other study ID # PCeo-17
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 9, 2018
Est. completion date June 30, 2020

Study information

Verified date March 2021
Source Scigenia GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Zeolite clinoptilolite is a volcanic mineral from the group of zeolites. The porous structure is associated with a large inner surface. Due to the anionic framework charge, ions (e.g., Pb^2+) can be absorbed or exchanged. The specific Panaceo PMA zeolite is approved as a class IIa medical device for the repair of the intestine inner lining. It is CE certified and complies with the relevant European Union regulations in terms of safety and effectiveness. Zeolite is known for its absorbing properties. Because of these properties and the results of several human studies, it warrants the investigation of possible effects on specific indications in human medicine, e.g. irritable bowel syndrome. The diagnosis "irritable bowel syndrome (IBS)" is according to the ROME Foundation, an US medical society. IBS is a disorder with dysfunction of the bowels, a latent inflammation is discussed. The present study aims to evaluate the following effects in patients with IBS: - Primary endpoint: effect on the symptoms of IBS. - Secondary endpoint: intestinal wall permeability, integrity of the tight junctions as measured by the change in zonulin concentration in the stool. - Further endpoints: - Inflammation parameters and anti-inflammatory laboratory parameters. - Biodiversity of the gastrointestinal microbiome. - histamine-associated parameters. - Constipation as a possible side effect. For this purpose, a double-blind randomized controlled trial (RCT) is realized prospectively in a monocentric outpatient-controlled study. The subjects take the test compound daily (verum, reference substance) for 12 weeks and document the intake of the study-substance, intake of medications, stool-frequency and consistency. They receive "before" and "after" the intervention phase a blood and stool analysis for the determination of parameters for intestinal wall integrity (zonulin) inflammation (hsCRP, interleukin-10, calprotectin), histamine metabolism, microbiome diversity. The pilot study is realized ahead of the detailed planning of a later main study.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date June 30, 2020
Est. primary completion date June 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Frequency of discomfort or pain in the abdomen in the last 3 months, more than 1 day per week. - Start of the discomfort or pain more than 6 months ago. - Improvement of the discomfort or pain associated with bowel movements sometimes, often, frequently, always. - Association of the discomfort or pain with a frequency change in bowel movements sometimes, often, frequently, always. - Association of the discomfort or pain with a change in stool-consistency sometimes, often, frequently, always. Exclusion Criteria: - Age: younger than 18, older than 80. - Diagnosed inflammatory bowel disease (M. Crohn, Colitis Ulcerosa) - Diagnosed nutritional idiosyncrasy - Cancer treatment in the last 12 weeks - Depression in the last 12 weeks - Intake of weight loss supporting medication (Lipase inhibitors) - Alcohol, nicotine, drug-abuse - Status after organ-transplantation, intake of immunosuppressants - Acute or chronic neurologic or psychiatric disease - Acute or chronic heart disease or kidney disease - Acute or chronic liver damage or any other organ damages - Transient severe obstipation in the last 4 weeks - Transient acute diarrhea in the last 4 weeks (e.g. intestinal infection) - Intestinal cancer - Intake of Panaceo MED or other Zeolite in the last 4 weeks - Type I Diabetes or severe metabolic disease - Infection with fever in the last 4 weeks - Intake of cortisone or antibiotics in the last 4 weeks - Planed journey of more than 14 days in the next 12 weeks (change of nutritional habits)

Study Design


Intervention

Other:
Zeolite
The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.

Locations

Country Name City State
Austria SCIgenia GmbH Vienna

Sponsors (1)

Lead Sponsor Collaborator
Scigenia GmbH

Country where clinical trial is conducted

Austria, 

References & Publications (1)

Lamprecht M, Bogner S, Steinbauer K, Schuetz B, Greilberger JF, Leber B, Wagner B, Zinser E, Petek T, Wallner-Liebmann S, Oberwinkler T, Bachl N, Schippinger G. Effects of zeolite supplementation on parameters of intestinal barrier integrity, inflammation, redoxbiology and performance in aerobically trained subjects. J Int Soc Sports Nutr. 2015 Oct 20;12:40. doi: 10.1186/s12970-015-0101-z. eCollection 2015. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Change of permeability (Leaky-Gut) Zonulin (< 55 ng/ml) in stool 3 months
Other Change of bowel inflammation Calprotectin (< 50 mg/l) in stool 3 months
Other Change of permeability of mucosa Alpha 1-Antitrypsin (< 27,5 mg/dl) in stool 3 months
Other Change of the inflammation mediator Histamin (< 600 ng/ml) in stool 3 months
Other Efficacy of binding and elimination of ammoniak Ammoniak (11-51 µmol/l) in blood / serum 3 months
Other Change of inflammation high sensitivity C-reactive protein (mg/l) in blood / serum 3 months
Other Change of anti-inflammatory mediator Interleukin-10 (< 9,1 pg/ml) in blood / serum 3 months
Other Possible release of metal ions Aluminium (< 11 µg/l) in blood / serum 3 months
Other Change of histamin metabolism Di-Amino-Oxydase (> 10 U/ml) in blood / serum 3 months
Primary Abdominal discomfort or pain Frequency: 0 - never, 1 - less than once / month, 2 - once / month, 3 - two-three days / month, 4 - once per week, 5 - more than once per week, 6 - every day. 3 months
Primary Symptom improvement with defaecation 0 - never or rarely, 1 - sometimes, 2 - often, 3 - frequently, 4 - always. 3 months
Primary Stool frequency associated with abdominal discomfort or pain (more or less frequent) 0 - never or rarely, 1 - sometimes, 2 - often, 3 - frequently, 4 - always. 3 months
Primary Stool consistency associated with abdominal discomfort or pain (softer or harder) 0 - never or rarely, 1 - sometimes, 2 - often, 3 - frequently, 4 - always. 3 months
Secondary Stool laboratory parameter: Firmicutes Genotyping of bacteria in stool, before and after intake of study substance; Prevalence Firmicutes (CFU/g stool) 3 months
Secondary Stool laboratory parameter: Bacteroidetes Genotyping of bacteria in stool, before and after intake of study substance; Prevalence Bacteroidetes (CFU/g stool) 3 months
Secondary Stool laboratory parameter: Ratio: Bacteroidetes/Firmicutes Genotyping of bacteria in stool, before and after intake of study substance; Computation of Ratio: Bacteroidetes/Firmicutes 3 months
Secondary Stool laboratory parameter: Butyrat Producers Genotyping of bacteria in stool, before and after intake of study substance; Prevalence of Butyratproducing bacteria (CFU/g stool) 3 months
Secondary Stool laboratory parameter: Clostridia Genotyping of bacteria in stool, before and after intake of study substance; Prevalence of Clostridia (CFU/g stool) 3 months
Secondary Stool laboratory parameter: Histaminproducers, Genotyping of bacteria in stool, before and after intake of study substance; Prevalence of Histaminproducing bacteria (CFU/g stool) 3 months
Secondary Stool laboratory parameter: H2S producers Genotyping of bacteria in stool, before and after intake of study substance; Prevalence of H2S-producing bacteria (CFU/g stool) 3 months
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A